Med-SBMANCT06862596
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 3 of 8 entries
- Site details revised at 5 of 5 sites
- Minor Start date: Feb 26, 2025 to Feb 28, 2025
- Site contacts updated at 1 of 5 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score
Timeframe: at 4weeks
Secondary (8)
ALSFRS-R Score
Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) score
Grip strength
Tongue pressure
Timed walk test (4.6 meters)
Show 3 moreShow less
6-minute walk test
Respiratory function test (Forced Vital Capacity (FVC))
Respiratory function test (Peak Expiratory Flow (PEF))
Arms and interventions
Mexiletine groupActive comparator
Placebo groupPlacebo comparator
Drugs: Mexiletine hydrochloride
Other: Placebo
Sites
5 sites in 1 country